DOCSLIB.ORG

Drug Interactions of Sglt2 Inhibitors (Gliflozins) Involving Ugt Enzymes Dr

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Drug Interactions of Sglt2 Inhibitors (Gliflozins) Involving Ugt Enzymes Dr Archives of Diabetes and Endocrine System ISSN 2638-4981 Volume 2, Issue 2, 2019, PP: 13-16 Drug Interactions of sglt2 Inhibitors (Gliflozins) Involving ugt Enzymes Dr. Naina Mohamed Pakkir Maideen PhD, [email protected] Pharmacologist, Dubai Health Authority, PB No: 4545, Dubai, UAE. *Corresponding Author: Dr. Naina Mohamed Pakkir Maideen PhD, Pharmacologist, Dubai Health Authority, PB No: 4545, Dubai, UAE. Abstract Sodium glucose cotransporter 2 (SGLT2) inhibitors are antidiabetic drugs which are useful in the management of blood sugar of patients with type 2 diabetes, along with diet and exercise. The SGLT2 inhibitors are the substrates of UGT enzymes and SGLT2 inhibitorss uch as Dapagliflozin, Canagliflozin and Ipragliflozin are metabolised by glucuronidation predominantly by UGT1A9 enzyme. In addition, Canagliflozin and Ipragliflozin are also metabolised by UGT2B4. The drugs inhibiting or inducing UGT1A9 and other UGT enzymes are expected to alter the pharmacokinetics of SGLT2 inhibitors. Although the plasma exposure of Dapagliflozin and Canagliflozin are increased slightly by the concomitant use of Mefenamic acid and Probenecid respectively, these interactions were not considered clinically meaningful. Rifampicin and other UGT inducers such as Phenytoin, Phenobarbital and Ritonavir were observed to decrease the plasma levels of Canagliflozin, insignificantly. Based on the results of this review, SGLT2 inhibitors could be coadministered with any medicines without dosage adjustments except Canagliflozin, which needs higher dosage while using along with UGT enzyme inducers. Keywords : Drug interactions; SGLT2 inhibitors; UGT Enzymes; Canagliflozin; Dapagliflozin; Empagliflozin; Ertugliflozin; Ipragliflozin; Luseogliflozin; Tofogliflozin. Introduction drug by the administration of other drug(s), supplements, Sodium glucose cotransporter 2 (SGLT2) inhibitors smokingModification or alcohol of effects is termed drugof interactionone [3, 4]. are antidiabetic drugs which are useful in the management of blood sugar of patients with type 2 Uridine 5’-diphospho-glucuronosyltransferase (UDP- diabetes, along with diet and exercise. The members of this class of antidiabetic medications approved glucuronosyltransferase, UGT) enzymes are involved by U.S. Food and Drug Administration (FDA) include consistsin Phase of II metabolismUGT1 and UGT2(glucuronidation) families that of furthercertain divideddrugs. Theas subfamilies superfamily of UGT1A,of human UGT2A, UGT and enzymes UGT2B Canagliflozin, Dapagliflozin, Empagliflozin, and and the members of these families include UGT1A1, areErtugliflozin. approved Inin addition,Japan [1]. the SGLT2 other inhibitors SGLT2 inhibitors prevent UGT1A3, UGT1A4, UGT1A6, UGT1A7, UGT1A8, thesuch reabsorption as Ipragliflozin, of glucose Luseogliflozin, and facilitate and Tofogliflozinits excretion UGT1A9, UGT1A10, UGT2B4, UGT2B7, UGT2B15 and UGT2B17 [5]. The SGLT2 inhibitors such as through urine by inhibiting Sodium-glucose co- transporter-2 in the proximal convoluted tubule, metabolised by glucuronidation predominantly which results in decrease in blood sugar [2]. Dapagliflozin, Canagliflozin and Ipragliflozin are The probability of drug interactions is higher among diabetic patients since they use number by UGT1A9 enzyme. In addition, Canagliflozin and of comedications to treat their comorbidities. byIpragliflozin UGT1A3, UGT1A8,are also UGT1A9metabolised and UGT2B7 by UGT2B4. [6]. The other SGLT2 inhibitor, Empagliflozin is metabolised Archives of Diabetes and Endocrine System V2 . I2 . 2019 13 Drug Interactions of sglt2 Inhibitors (Gliflozins) Involving ugt Enzymes The drugs inhibiting or inducing UGT1A9 and other did not result in any alteration in the clearance of Concomitant use of Canagliflozin and Acetaminophen interactions of SGLT2 inhibitors. Acetaminophen [12]. UGT enzymes may play a major role in the drug Mefenamic Acid Warfarin Warfarin is an oral anticoagulant drug and it is used mainly to manage conditions such as Deep vein Mefenamic acid is a Non-steroidal anti-inflammatory drug (NSAID) and it has been identified as a strong theinhibitor concurrent of UGT1A9 use ofenzyme. Mefenamic The plasma acid. However, exposure no of thrombosis (DVT) and Pulmonary embolism (PE) and Dapagliflozin observed to be increased modestly by The pharmacokinetics parameters of Warfarin was to prevent stroke in patients with atrial fibrillation [13]. drugs concomitantly [7]. dosage adjustments are required while using these [14] or Probenecid not affected by the concurrent use of Dapagliflozin DigoxinCanagliflozin [15]. Probenecid is an agent to treat gout and hyperuricemia Digoxin is a cardiac glycoside and its coadministration UGT1A9. Concomitant administration of Probenecid and it is a known inhibitor of UGT enzymes including result in clinically meaningful interaction, in health with Dapagliflozin [14] or Canagliflozin [15],did not participants. whichand Canagliflozin is considered in clinically healthy participantsirrelevant [8]. resulted in slight increase in the plasma exposure of Canagliflozin, Simvastatin Rifampicin Simvastatin is an agent useful to treat dyslipidemia Rifampicin is an anti-mycobacterial antibiotic and it is used in the treatment of tuberculosis and leprosy [9]. and its concomitant use with Dapagliflozin [14] or plasma exposure of Simvastatin and Simvastatin acid, Canagliflozin [16] resulted in slight increase in the UGT1A9 and the coadministration of Rifampicin in healthy participants. However, these interactions Rifampicin is an inducer of many enzymes including with Dapagliflozin lead to slight decrease in plasma wereValsartan not considered clinically significant. exposure of Dapagliflozin. However, the drug was not considered clinically meaningful and no Valsartan is an angiotensin receptor blocker (ARB) interaction between Dapagliflozin and Rifampicin Nevertheless, and it is used to treat hypertension, heart failure dosage adjustments are required [7]. modestly in healthy participants who took Rifampicin Valsartan in healthy participants, lead to slight the plasma exposure of Canagliflozin was decreased and others. Coadministration of Dapagliflozin and increase in the plasma exposure of Valsartan, which is along with Canagliflozin and the monitoring of blood not clinically important [14]. Other UGT Enzyme Inducers sugar may be required [8]. Oral contraceptives The plasma exposure of Oral contraceptives containing enhanced by the coadministration of UGT inducers suchThe asUGT-mediated Phenytoin, Phenobarbital metabolism or of Ritonavir Canagliflozin resulting is slightly by while Ethinyl estradiol and Levonorgestrel was increased [17] d Oral [10]. Canagliflozin [15] Empagliflozin in decreased plasma concentrations of Canagliflozin contraceptives. Hence, the patients taking Canagliflozin along id not affect the pharmacokinetics of Thiazide Diuretics 300mg,with UGT if needed enzyme [11]. inducers are recommended to increase the dose of Canagliflozin from 100mg to Acetaminophen (Paracetamol) with hypertension and edema. Coadministration of Thiazide diuretics help to manage the patients Acetaminophen is an antipyretic and analgesic medication and it is metabolised primarily by UGT1A6 Canagliflozin and Hydrochlorothiazide in healthy nt. changes in pharmacokinetics of either drugs [18]. participants did not produce any clinically significant enzyme14 and by UGT1A9 enzyme with lesser exteArchives of Diabetes and Endocrine System V2 . I2 . 2019 Drug Interactions of sglt2 Inhibitors (Gliflozins) Involving ugt Enzymes Other Oral antidiabetic drugs [2] Dandona P, Chaudhuri A. Sodium-glucose co-transporter 2 inhibitors for type 2 diabetes The plasma exposure of Glyburide and Metformin mellitus: An overview for the primary care did not get altered by their co-administration with hile the pharmacokinetics practice. 2017 May;71(5):e12937. parameters of physician. International journal of clinical andCanagliflozin Sitagliptin [16]were wnot altered by the addition of [3] Maideen NM, Balasubramaniam R. Pioglitazone, Metformin, GlimepirideMoreover, Pharmacologically relevant drug interactions of sulfonylurea antidiabetics with common herbs. Dapagliflozin, in healthy subjects [19]. Journal of Herbmed Pharmacology. 2018;7(3). there was no significant interaction observed in antidiabetic drugs such as Metformin, Sitagliptin, [4] study participants taking Ipragliflozin and other oral and in Japanese patients with type 2 diabetes who AmericanMohamed N,Journal Maideen of P.Physiology, Thiazolidinediones Biochemistry and Pioglitazone, Glimepiride, Miglitol or Mitiglinide [20] andtheir Pharmacology. Drug Interactions 2018;8(2):47-54. involving CYP enzymes. tookConclusion Dapagliflozin and Voglibose concomitantly [21]. [5] glucuronosyltransferases and clinical drug-drug The SGLT2 inhibitors are the substrates of UGT interactions.Kiang TK, PharmacologyEnsom MH, &Chang therapeutics. TK. 2005UDP- Apr 1;106(1):97-132. enzymes and SGLT2 inhibitors such as Dapagliflozin, [6] Kashiwagi A, Maegawa H. Metabolic and TheCanagliflozin drugs inhibiting and Ipragliflozin UGT1A9 such are as metabolisedMefenamic acid by andglucuronidation Probenecid slightly predominantly increased by the UGT1A9 plasma exposure enzyme. glucose cotransporter 2 inhibitors on cardio-renal protectionhemodynamic in theeffects treatment of sodiumof patients-dependent with Rifampicin and other UGT inducers such as Phenytoin, type 2 diabetes mellitus. Journal of diabetes Phenobarbitalof Dapagliflozin and Ritonavirand Canagliflozin were observed
Load more

Recommended publications
  • Download Product Catalog
    Total Quality Medications Product Portfolio Rx Product name Dosage form Generic name Pack size Indications A- Alimentary tract and metabolism A02B – Proton pump inhibitor Omecarbex 20 mg H.G Cap Omeprazole +Na 20 Caps Acid reflux and Ulcers Omecarbex 40 mg H.G Cap Carbonate 20 Caps Acid reflux and Ulcers A06A - Laxatives Amiprostone 8 mcg S.G Cap Lubiprostone 20 Capsules Laxative Amiprostone 24 mcg S.G Cap Lubiprostone 10 Capsules Laxative A07A- Intestinal Anti-infective Anti-diarrheal Gastrobiotic 200 mg Tablets Rifiximin 20 Tablets Antidiarrheal Gastrobiotic 550 mg Tablets Rifiximin 30 Tablets Antidiarrheal Nitazode 100 mg/5 ml Suspension Nitazoxanide Bottle 60 ml Antiprotozoal A10B- Oral Anti -diabetics A10-BD - Oral hypoglycemic associations Glimepiride+ Improve glycemic control for type 2 Glimepiride plus 4/30 Tablets 30 Tablets Pioglitazone Hcl diabetes Glimepiride+ Improve glycemic control for type 2 Glimepiride plus 2/30 Tablets 30 Tablets Pioglitazone Hcl diabetes Metformin Hcl + Improve glycemic control for type 2 Bioglitaplus 15/500 Tablets 20 Tablets Pioglitazone Hcl diabetes Metformin Hcl + Improve glycemic control for type 2 Bioglitaplus 15/850 Tablets 20 Tablets Pioglitazone Hcl diabetes A10BX - Other anti diabetics Control the elevation of blood sugar Megy One 10 mg Tablets Mitiglinide 20 Tablets after eating B- Blood and blood forming organs B01A - Anti-thrombotic agents Andorivaban 10 mg F.C Tablets Rivaroxaban 20 Tablets Anticoagulants Andorivaban 15 mg F.C Tablets Rivaroxaban 20 Tablets Anticoagulants Andorivaban 20
    [Show full text]
  • Treatment of Diabetes Mellitus
    TREATMENT OF DIABETES MELLITUS DIABETES is a condition that affects how the body makes energy from food. Food is broken down into sugar (glucose) in the body and released into the blood. When the blood sugar level rises after a meal, insulin responds to let the sugar into the cells to be used as energy. In diabetes, the body either does not make enough insulin or it stops responding to insulin as well as it should. This results in sugar staying in the blood and leads to serious health problems over time. DIAGNOSIS OF DIABETES1 • A1C Test: Lab test measuring average blood sugar over past two to three months • Fasting Blood Sugar Test: Lab test measuring blood sugar after eight hours of no food or drink • Oral Glucose Tolerance Test (OGTT): Measures blood sugar before and two hours after drinking a specific sugary liquid • Random Blood Sugar Test: Measures blood sugar at a moment in time, without any kind of preparation (like fasting) FASTING BLOOD ORAL GLUCOSE TOLERANCE RANDOM BLOOD RESULT A1C TEST SUGAR TEST TEST SUGAR TEST Diabetes ≥ 6.5% ≥126 mg/dL ≥ 200 mg/dL ≥ 200 mg/dL Prediabetes 5.7 – 6.4% 100 – 125 mg/dL 140 – 199 mg/dL N/A Normal < 5.7% ≤99 mg/dL < 140 mg/dL N/A NON-DRUG TREATMENTS2 THERAPY COST WHAT TO EXPECT Diet (Mediterranean diet) and exercise (30 minutes a day, five days a week of moderate- Weight loss $-$$ intensity exercise); 7% weight loss decreases risk of diabetes3 Psychological intervention $$-$$$ Psychotherapy may reduce diabetic distress and improve glycemic control4,5 nationalcooperativerx.com PRESCRIPTION TREATMENTS
    [Show full text]
  • 295-304 Research Article Pulsatile Drug Delivery of Chitosan Co
    Available online www.jocpr.com Journal of Chemical and Pharmaceutical Research, 2015, 7(12):295-304 ISSN : 0975-7384 Research Article CODEN(USA) : JCPRC5 Pulsatile drug delivery of chitosan coated beads of miglitol with fast dissolving glimepiride tablet Bhise S. H.*, Surve B. S., Aloorkar N. H., Majumdar S. H. and Kulkarni A. S. Department of Pharmaceutics, Satara College of Pharmacy, Satara, Shivaji University, Maharashtra, India _____________________________________________________________________________________________ ABSTRACT : Pulsatile drug delivery system was developed which have three parts fast dissolving tablet of glimepiride, sustained release chitosan coated microbeads of miglitol and plug of HPMC E5 and spray dried lactose. After pre- formulation studies fast dissolving tablets were prepared by direct compression method; which shows instant drug release and % CDR of glimepiride fast dissolving tablet was found to be 70.81%. polymer plug have lag time 2.30 hr, chitosan coated miglitol beads shows sustained release upto 81.66% .this system is evaluated using different physicochemical parameters and in-vitro studies. Result suggests that the system can be applicable for diabetes treatment. Key words: Pulsatile, microbeads, sustained release, miglitol, glimepiride. _____________________________________________________________________________________________ INTRODUCTION Oral controlled drug delivery systems represent the most popular form of controlled drug delivery system which release the drug with constant or variable release rates.[1] Dose of drug, reduced dosage frequency, avoidance of side effects, and improved patient compliance. However, there are certain conditions for which such a release pattern is not suitable. These conditions demand release of drug after a lag time. In other words, it is required that the drug should not be released at all during the initial phase of dosage form administration.
    [Show full text]
  • Effect of the Α-Glucosidase Inhibitor Miglitol on the Glucose Profile in Japanese Type 2 Diabetic Patients Receiving Multiple Daily Insulin Injections
    Endocrine Journal 2012, 59 (4), 345-352 ORIGINAL Effect of the α-glucosidase inhibitor miglitol on the glucose profile in Japanese type 2 diabetic patients receiving multiple daily insulin injections Hiroyuki Kato, Akio Ohta, Suzuko Kobayashi, Satoshi Ishii, Yukiyoshi Sada, Hidetoshi Kobayashi, Shintaro Ohmori, Akihiko Kondo, Takuyuki Katabami, Junro Fuse, Hisashi Fukuda, Yoshio Nagai and Yasushi Tanaka Department of Internal Medicine, Division of Metabolism and Endocrinology, St. Marianna University School of Medicine, Kawasaki 216-8511, Japan Abstract. Strict postprandial glycemic control may have a preventive effect on atherogenesis in patients with type 2 diabetes. The α-glucosidase inhibitor (α-GI) miglitol is useful for controlling the early postprandial increase of glucose, but the combined effect of miglitol and multiple daily insulin injections (MDI) on glucose excursion has not been evaluated. First, we retrospectively compared the daily glucose profile, evaluated by self-monitoring of blood glucose (SMBG) at nine times on the day before discharge from hospital, between type 2 diabetic patients receiving MDI (n=81) or MDI plus miglitol at 150 mg daily (n=24). Second, we prospectively examined the effect of adding miglitol to MDI on the daily glucose profile (SMBG) in 19 other type 2 diabetic patients. Although the daily insulin dosage and the glucose level before meals did not differ between the two groups, the 1-h postprandial glucose level after each meal, 2-h glucose level after lunch and dinner, mean and standard deviation of glucose, and amplitude of glucose excursion were significantly lower or smaller in the MDI plus miglitol group than in the MDI group.
    [Show full text]
  • Specifications of Approved Drug Compound Library
    Annexure-I : Specifications of Approved drug compound library The compounds should be structurally diverse, medicinally active, and cell permeable Compounds should have rich documentation with structure, Target, Activity and IC50 should be known Compounds which are supplied should have been validated by NMR and HPLC to ensure high purity Each compound should be supplied as 10mM solution in DMSO and at least 100µl of each compound should be supplied. Compounds should be supplied in screw capped vial arranged as 96 well plate format.
    [Show full text]
  • Dapagliflozin – Structure, Synthesis, and New Indications
    Pharmacia 68(3): 591–596 DOI 10.3897/pharmacia.68.e70626 Review Article Dapagliflozin – structure, synthesis, and new indications Stefan Balkanski1 1 Bulgarian Pharmaceutical Union, Sofia, Bulgaria Corresponding author: Stefan Balkanski ([email protected]) Received 24 June 2021 ♦ Accepted 4 July 2021 ♦ Published 4 August 2021 Citation: Balkanski S (2021) Dapagliflozin – structure, synthesis, and new indications. Pharmacia 68(3): 591–596.https://doi. org/10.3897/pharmacia.68.e70626 Abstract Dapagliflozin is a sodium-glucose co-transporter-2 (SGLT2) inhibitors used in the treatment of patients with type 2 diabetes. An aryl glycoside with significant effect as glucose-lowering agents, Dapagliflozin also has indication for patients with Heart Failure and Chronic Kidney Disease. This review examines the structure, synthesis, analysis, structure activity relationship and uses of the prod- uct. The studies behind this drug have opened the doors for the new line of treatment – a drug that reduces blood glucoses, decreases the rate of heart failures, and has a positive effect on patients with chronic kidney disease. Keywords Dapagliflozin, SGLT2-inhibitor, diabetes, heart failure Structure of dapagliflozin against diabetes (Lee et al. 2005; Lemaire 2012; Mironova et al. 2017). Embodiments of (SGLT-2) inhibitors include C-glycosides have a remarkable rank in medicinal chemis- dapagliflozin, canagliflozin, empagliflozin and ipragliflozin, try as they are considered as universal natural products shown in Figure 1. It has molecular formula of C24H35ClO9. (Qinpei and Simon 2004). Selective sodium-dependent IUPAC name (2S,3R,4R,5S,6R)-2-[4-chloro-3-[(4- glucose cotransporter 2 (SGLT-2) inhibitors are potent ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)oxa- medicinal candidates of aryl glycosides that are functional ne-3,4,5-triol;(2S)-propane-1,2-diol;hydrate.
    [Show full text]
  • Supplementary Material
    Supplementary material Table S1. Search strategy performed on the following databases: PubMed, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL). 1. Randomi*ed study OR random allocation OR Randomi*ed controlled trial OR Random* Control* trial OR RCT Epidemiological study 2. sodium glucose cotransporter 2 OR sodium glucose cotransporter 2 inhibitor* OR sglt2 inhibitor* OR empagliflozin OR dapagliflozin OR canagliflozin OR ipragliflozin OR tofogliflozin OR ertugliflozin OR sotagliflozin OR sergliflozin OR remogliflozin 3. 1 AND 2 1 Table S2. Safety outcomes of empagliflozin and linagliptin combination therapy compared with empagliflozin or linagliptin monotherapy in treatment naïve type 2 diabetes patients Safety outcome Comparator 1 Comparator 2 I2 RR [95% CI] Number of events Number of events / / total subjects total subjects i. Empagliflozin + linagliptin vs empagliflozin monotherapy Empagliflozin + Empagliflozin linagliptin monotherapy ≥ 1 AE(s) 202/272 203/270 77% 0.99 [0.81, 1.21] ≥ 1 drug-related 37/272 38/270 0% 0.97 [0.64, 1.47] AE(s) ≥ 1 serious AE(s) 13/272 19/270 0% 0.68 [0.34, 1.35] Hypoglycaemia* 0/272 5/270 0% 0.18 [0.02, 1.56] UTI 32/272 25/270 29% 1.28 [0.70, 2.35] Events suggestive 12/272 13/270 9% 0.92 [0.40, 2.09] of genital infection i. Empagliflozin + linagliptin vs linagliptin monotherapy Empagliflozin + Linagliptin linagliptin monotherapy ≥ 1 AE(s) 202/272 97/135 0% 1.03 [0.91, 1.17] ≥ 1 drug-related 37/272 17/135 0% 1.08 [0.63, 1.84] AE(s) ≥ 1 serious AE(s) 13/272 2/135 0% 3.22 [0.74, 14.07] Hypoglycaemia* 0/272 1/135 NA 0.17 [0.01, 4.07] UTI 32/272 12/135 0% 1.32 [0.70, 2.49] Events suggestive 12/272 4/135 0% 1.45 [0.47, 4.47] of genital infection RR, relative risk; AE, adverse event; UTI, urinary tract infection.
    [Show full text]
  • Summary of Investigation Results Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors
    Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material for the convenience of users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail. Summary of investigation results Sodium-glucose co-transporter 2 (SGLT2) inhibitors September 15, 2015 Non-proprietary name a. Canagliflozin hydrate b. Dapagliflozin propylene glycolate hydrate c. Empagliflozin d. Ipragliflozin L-proline e. Luseogliflozin hydrate f. Tofogliflozin hydrate Brand name (Marketing authorization holder) a. Canaglu Tablets 100 mg (Mitsubishi Tanabe Pharma Corporation) b. Forxiga Tablets 5 mg and 10 mg (AstraZeneca K.K.) c. Jardiance Tablets 10 mg and 25 mg (Nippon Boehringer Ingelheim Co., Ltd.) d. Suglat Tablets 25 mg and 50 mg (Astellas Pharma Inc.) e. Lusefi Tablets 2.5 mg and 5 mg (Taisho Pharmaceutical Co., Ltd.) f. Apleway Tablets 20 mg (Sanofi K.K.) and Deberza Tablets 20 mg (Kowa Company, Ltd.) Indications Type 2 diabetes mellitus Summary of revision 1. Precautions regarding ketoacidosis should be added in the Important Precautions section for the above products from a to f. 2. “Ketoacidosis” should be newly added in the Clinically significant adverse reaction section for the above products from a to f. 3. “Sepsis” should be added to the “Pyelonephritis” subsection in the Important Precautions section for the above products from a to f. Pharmaceuticals and Medical Devices Agency Office of Safety I 3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan E-mail: [email protected] Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material for the convenience of users.
    [Show full text]
  • Steglujan, INN-Ertugliflozin-Sitagliptin
    25 January 2018 EMA/86941/2018 Committee for Medicinal Products for Human Use (CHMP) Assessment report Steglujan International non-proprietary name: ertugliflozin / sitagliptin Procedure No. EMEA/H/C/004313/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure .............................................. 7 1.1. Submission of the dossier ...................................................................................... 7 1.2. Steps taken for the assessment of the product ......................................................... 8 2. Scientific discussion ................................................................................ 9 2.1. Problem statement ............................................................................................... 9 2.1.1. Disease or condition ........................................................................................... 9 2.1.2. Epidemiology .................................................................................................... 9 2.1.3. Clinical presentation ..........................................................................................
    [Show full text]
  • Steglujan (Ertugliflozin/Sitagliptin), Segluromet
    Steglatro™ (ertugliflozin), Steglujan™ (ertugliflozin/sitagliptin), Segluromet™ (ertugliflozin/metformin) – New drug approval • On December 19, 2017, the FDA approved Merck’s Steglatro (ertugliflozin), Steglujan (ertugliflozin/sitagliptin), and Segluromet (ertugliflozin/metformin) as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (T2DM). — Steglujan is indicated when treatment with both ertugliflozin and sitagliptin is appropriate. — Segluromet is indicated when patients are not adequately controlled on a regimen containing ertugliflozin or metformin, or in patients who are already treated with both ertugliflozin and metformin. — These drugs are not recommended in patients with type 1 diabetes mellitus (T1DM) or for the treatment of diabetic ketoacidosis. — Steglujan has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using Steglujan. • Ertugliflozin is the fourth sodium-glucose co-transoporter-2 (SGLT2) inhibitor approved by the FDA. Other marketed SGLT2 inhibitors include Jardiance® (empagliflozin), Farxiga® (dapagliflozin), and Invokana® (canagliflozin). • The efficacy and safety of ertugliflozin were evaluated in multiple clinical studies involving patients with T2DM. Ertugliflozin was studied as monotherapy and in combination with metformin and/or a dipeptidyl peptidase 4 (DPP-4) inhibitor. Ertugliflozin was also studied in combination with other antidiabetic medications, including insulin and a sulfonylurea, and in T2DM patients with moderate renal impairment. — In patients with T2DM, treatment with ertugliflozin, ertugliflozin + sitagliptin, and ertugliflozin + metformin reduced hemoglobin A1c (HbA1c) vs. placebo or the active comparator. — In patients with T2DM and moderate renal impairment, treatment with ertugliflozin did not result in a reduction in HbA1c vs.
    [Show full text]
  • SGLT2 Inhibitors and Kidney Outcomes in Patients with Chronic Kidney Disease
    Journal of Clinical Medicine Editorial SGLT2 Inhibitors and Kidney Outcomes in Patients with Chronic Kidney Disease Swetha R. Kanduri 1 , Karthik Kovvuru 1, Panupong Hansrivijit 2 , Charat Thongprayoon 3, Saraschandra Vallabhajosyula 4, Aleksandra I. Pivovarova 5 , Api Chewcharat 3, Vishnu Garla 6, Juan Medaura 5 and Wisit Cheungpasitporn 3,5,* 1 Department of Nephrology, Ochsner Medical Center, New Orleans, LA 70121, USA; [email protected] (S.R.K.); [email protected] (K.K.) 2 Department of Internal Medicine, University of Pittsburgh Medical Center Pinnacle, Harrisburg, PA 17105, USA; [email protected] 3 Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN 55905, USA; [email protected] (C.T.); [email protected] (A.C.) 4 Section of Interventional Cardiology, Division of Cardiovascular Medicine, Department of Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA; [email protected] 5 Division of Nephrology, Department of Medicine, University of Mississippi Medical Center, Jackson, MS 39156, USA; [email protected] (A.I.P.); [email protected] (J.M.) 6 Department of Internal Medicine and Mississippi Center for Clinical and Translational Research, University of Mississippi Medical Center, Jackson, MS 39156, USA; [email protected] * Correspondence: [email protected] Received: 20 August 2020; Accepted: 20 August 2020; Published: 24 August 2020 Abstract: Globally, diabetes mellitus is a leading cause of kidney disease, with a critical percent of patients approaching end-stage kidney disease. In the current era, sodium-glucose co-transporter 2 inhibitors (SGLT2i) have emerged as phenomenal agents in halting the progression of kidney disease. Positive effects of SGLT2i are centered on multiple mechanisms, including glycosuric effects, tubule—glomerular feedback, antioxidant, anti-fibrotic, natriuretic, and reduction in cortical hypoxia, alteration in energy metabolism.
    [Show full text]
  • Newer Diabetes Treatments Drug Class Update with New Drug Evaluation: Semaglutide and Ertugliflozin
    © Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 | Fax 503-947-1119 Newer Diabetes Treatments Drug Class Update with New Drug Evaluation: Semaglutide and Ertugliflozin Date of Review: July 2018 Date of Last Review: September 2017 End Date of Literature Search: 05/23/2018 Generic Name: semaglutide Brand Name (Manufacturer): Ozempic® (Novo Nordisk) Generic Name: ertugliflozin, ertugliflozin/sitagliptin, ertugliflozin/metformin Brand Name (Manufacturer): Steglatro™, Steglujan™, Segluromet™ (Merck & Co., Inc.) Dossier Received: ertugliflozin (yes), semaglutide (no) Current Status of PDL Class: See Appendix 1. Purpose for Class Update: To evaluate the safety and efficacy of semaglutide and ertugliflozin (and combinations) which were recently approved for blood glucose lowering in patients with type 2 diabetes mellitus (T2DM). High quality new evidence published since the last review will also be presented. Research Questions: 1. In patients with T2DM, is there any new comparative evidence for non-insulin antidiabetic therapies based on surrogate efficacy outcomes (e.g., hemoglobin A1c [HbA1c]) and long-term clinically meaningful effectiveness outcomes (e.g., microvascular outcomes, macrovascular outcomes and mortality)? 2. In patients with T2DM, is there any new comparative evidence for non-insulin diabetes treatments based on harms outcomes (e.g., severe hypoglycemia, heart failure, diabetic ketoacidosis, pancreatitis, etc.)? 3. Are there subpopulations of patients with T2DM for which specific therapies may be more effective or associated with less harm? 4. What are the efficacy and harms evidence for the two new non-insulin diabetes treatments, ertugliflozin and semaglutide? Conclusions: A Drug Effectiveness Review Project (DERP) update on newer diabetes therapies, three new guidelines/standards, one new randomized controlled trial and two new drug reviews were reviewed for this class update.
    [Show full text]